|
1
|
Poruk KE and Weiss MJ: The current state
of surgery for pancreatic cancer. Minerva Gastroenterol Dietol.
61:101–115. 2015.PubMed/NCBI
|
|
2
|
Okabayashi T, Shima Y, Kosaki T, Sumiyoshi
T, Kozuki A, Iiyama T, Takezaki Y, Kobayashi M, Nishimori I, Ogawa
Y and Hanazaki K: Invasive carcinoma derived from branch duct-type
IPMN may be a more aggressive neoplasm than that derived from main
duct-type IPMN. Oncol Lett. 5:1819–1825. 2013.PubMed/NCBI
|
|
3
|
Nakata K, Nagai E, Ohuchida K, Aishima S,
Hayashi A, Miyasaka Y, Yu J, Mizumoto K, Tanaka M and Tsuneyoshi M:
REG4 is associated with carcinogenesis in the ‘intestinal’ pathway
of intraductal papillary mucinous neoplasms. Mod Pathol.
22:460–468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakayama K, Ishida N, Shirane M, Inomata
A, Inoue T, Shishido N, Horii I, Loh DY and Nakayama K: Mice
lacking p27(Kip1) display increased body size, multiple organ
hyperplasia, retinal dysplasia, and pituitary tumors. Cell.
85:707–720. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Denicourt C and Dowdy SF: Cip/Kip
proteins: More than just CDKs inhibitors. Genes Dev. 18:851–855.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suzuki Y, Sugiyama M, Abe N, Fujioka Y and
Atomi Y: Immunohistochemical similarities between pancreatic
mucinous cystic tumor and ovarian mucinous cystic tumor. Pancreas.
36:e40–e46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alli E, Yang JM and Hait WN: Silencing of
stathmin induces tumor-suppressor function in breast cancer cell
lines harboring mutant p53. Oncogene. 26:1003–1012. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghosh R, Gu G, Tillman E, Yuan J, Wang Y,
Fazli L, Rennie PS and Kasper S: Increased expression and
differential phosphorylation of stathmin may promote prostate
cancer progression. Prostate. 67:1038–1052. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jeon TY, Han ME, Lee YW, Lee YS, Kim GH,
Song GA, Hur GY, Kim JY, Kim HJ, Yoon S, et al: Overexpression of
stathmin1 in the diffuse type of gastric cancer and its roles in
proliferation and migration of gastric cancer cells. Br J Cancer.
102:710–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singer S, Ehemann V, Brauckhoff A, Keith
M, Vreden S, Schirmacher P and Breuhahn K: Protumorigenic
overexpression of stathmin/Op18 by gain-of-function mutation in p53
in human hepatocarcinogenesis. Hepatology. 46:759–768. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kouzu Y, Uzawa K, Koike H, Saito K,
Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, et
al: Overexpression of stathmin in oral squamous-cell carcinoma:
Correlation with tumour progression and poor prognosis. Br J
Cancer. 94:717–723. 2006.PubMed/NCBI
|
|
12
|
Zheng P, Liu YX, Chen L, Liu XH, Xiao ZQ,
Zhao L, Li GQ, Zhou J, Ding YQ and Li JM: Stathmin, a new target of
PRL-3 identified by proteomic methods, plays a key role in
progression and metastasis of colorectal cancer. J Proteome Res.
9:4897–4905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim JY, Harvard C, You L, Xu Z,
Kuchenbecker K, Baehner R and Jablons D: Stathmin is overexpressed
in malignant mesothelioma. Anticancer Res. 27:39–44.
2007.PubMed/NCBI
|
|
14
|
Lin WC, Chen SC, Hu FC, Chueh SC, Pu YS,
Yu HJ and Huang KH: Expression of stathmin in localized upper
urinary tract urothelial carcinoma: Correlations with prognosis.
Urology. 74:1264–1269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Watanabe A, Suzuki H, Yokobori T,
Tsukagoshi M, Altan B, Kubo N, Suzuki S, Araki K, Wada S,
Kashiwabara K, et al: Stathmin1 regulates p27 expression,
proliferation and drug resistance, resulting in poor clinical
prognosis in cholangiocarcinoma. Cancer Sci. 105:690–696. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baldassarre G, Belletti B, Nicoloso MS,
Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V
and Colombatti A: p27(Kip1)-stathmin interaction influences sarcoma
cell migration and invasion. Cancer Cell. 7:51–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akhtar J, Wang Z, Yu C, Zhang ZP and Bi
MM: STMN-1 gene: A predictor of survival in stage iia esophageal
squamous cell carcinoma after Ivor-Lewis esophagectomy? Ann Surg
Oncol. 21:315–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Altan B, Yokobori T, Mochiki E, Ohno T,
Ogata K, Ogawa A, Yanai M, Kobayashi T, Luvsandagva B, Asao T and
Kuwano H: Nuclear karyopherin-α2 expression in primary lesions and
metastatic lymph nodes was associated with poor prognosis and
progression in gastric cancer. Carcinogenesis. 34:2314–2321. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suzuki S, Miyazaki T, Tanaka N, Sakai M,
Sano A, Inose T, Sohda M, Nakajima M, Kato H and Kuwano H:
Prognostic significance of CD151 expression in esophageal squamous
cell carcinoma with aggressive cell proliferation and invasiveness.
Ann Surg Oncol. 18:888–893. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karst AM, Levanon K, Duraisamy S, Liu JF,
Hirsch MS, Hecht JL and Drapkin R: Stathmin 1, a marker of PI3K
pathway activation and regulator of microtubule dynamics, is
expressed in early pelvic serous carcinomas. Gynecol Oncol.
123:5–12. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hao Z and Huang S: E3 ubiquitin ligase
Skp2 as an attractive target in cancer therapy. Front Biosci
(Landmark Ed). 20:474–490. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bhagirath D, Abrol N, Khan R, Sharma M,
Seth A and Sharma A: Expression of CD147, BIGH3 and Stathmin and
their potential role as diagnostic marker in patients with
urothelial carcinoma of the bladder. Clin Chim Acta. 413:1641–1646.
2012. View Article : Google Scholar : PubMed/NCBI
|
